Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy UltraTech Cement, Titan Company: Kunal Bothra

      Kunal Bothra of LKP Securities is of the view that one can buy UltraTech Cement and Titan Company.

    • Godrej Cons defensive buy, HCL tech may move up: Prakash Gaba

      Prakash Gaba, Technical Analyst at prakashgaba.com is of the view that Godrej Consumer is a defensive buy and feels that HCL Tech may move higher.

    • Prefer Maruti, Glenmark, Bharat Forge for long term: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one may prefer Maruti Suzuki, Glenmark Pharma and Bharat Forge for long term.

    • Sell Dabur India, Adani Ports: Rajat Bose

      Rajat Bose of rajatkbose.com recommends selling Dabur India and Adani Ports.

    • Sell Cipla, Glenmark Pharma looks weak: Rajat Bose

      Rajat Bose of rajatkbose.com recommends selling Cipla and feels that Glenmark Pharma looks weak.

    • Sell Glenmark Pharma, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends selling Glenmark Pharma.

    • Bull's Eye: Buy Glenmark, IRB Infra, Jai Corp, Bajaj Hind

      Jay Thakkar of ShareKhan advises buying Bajaj Hindusthan with a target of Rs 22.30.

    • Buy Tata Motors, pick Glenmark: Prakash Gaba

      Prakash Gaba of prakashgaba.com recommends buying Tata Motors and feels that one can pick Glenmark Pharma.

    • Glenmark Pharma may touch Rs 971, says Rajat Bose

      Rajat Bose of rajatkbose.com feels that Glenmark Pharma may touch Rs 971.

    • Positive on IT, fin services, logistics cos: Prabhudas L

      R Sreesankar, Head - Institutional Equities, Prabhudas Lilladher, says that while every player having offshore IT centre with higher concentration of its employee base in Chennai will invariably be impacted by the recent floods, he remains positive on the sector.

    • Glenmark Pharma, Bharat Forge look good: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that Glenmark Pharma and Bharat Forge looks good.

    • Like Kotak Bank, Colgate; buy India Cements: Prakash Gaba

      Prakash Gaba of prakashgaba.com likes Kotak Mahindra Bank with a target of Rs 695 and Colgate Palmolive with a target of Rs 1010-1020 and advises going long in India Cements.

    • Sell Dish TV; buy LIC Housing, TV18 Broadcast: Prakash Gaba

      Prakash Gaba of prakashgaba.com recommends selling Dish TV and advises buying LIC Housing and TV18 Broadcast.

    • Go long in Mindtree, Tata Elxsi: Amit Harchekar

      Amit Harchekar of APLUS Analytics advises going long in Mindtree and Tata Elxsi and suggests shorting Oriental Bank of Commerce and Glenmark Pharma.

    • Cummins India may touch Rs 1175: Ajay Bodke

      Ajay Bodke of Prabhudas Lilladher is of the view that Cummins India may touch Rs 1175 and Jubilant Life Sciences may move to Rs 578.

    • 6 trading stocks for short term gain

      Aditya Agarwal of Way2Wealth Securities is of the view that one may sell State Bank of India with a target of Rs 222-220.

    • Upbeat on Glenmark, Wockhardt, Ajanta Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com is upbeat on Glenmark Pharma, Wockhardt and Ajanta Pharma.

    • Short Idea, Glenmark; buy Colgate: Prakash Gaba

      Watch the interview of Prakash Gaba of prakashgaba.com with Latha Venkatesh & Sonia Shenoy on CNBC-TV18, in which he shared his readings and outlook on the market, specific stocks and sectors.

    • Buy Glenmark Pharma, Lupin: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Glenmark Pharma and Lupin.

    • Buy Glenmark Pharma on dips, says Sameet Chavan

      Sameet Chavan, Technical Analyst at Angel Broking is of the view that one can buy Glenmark Pharma on dips for a target of Rs 1010.

    • Go long in Arvind, sell Glenmark Pharma: Chandan Taparia

      Chandan Taparia of Anand Rathi Securities recommends going long in Arvind and advises selling Glenmark Pharma.

    • Underweight on pharma, IT space: Sanjay Dutt

      Sanjay Dutt, Director of Quantum Securities is underweight on pharma and IT space.

    • Jubilant Life Sciences may test Rs 570, says Ajay Bodke

      Ajay Bodke of Prabhudas Lilladher feels that Jubilant Life Sciences may test Rs 570 and Glenmark Pharma may go up to Rs 1186.

    • Go long in Glenmark Pharma, says Gaurav Bissa

      Gaurav Bissa, Derivatives Analyst at LKP Securities is of the view that one may go long in Glenmark Futures for target of Rs 1,000.

    • Anish Damania bullish on midcap pharma stocks

      Anish Damania, CEO of IDFC Securities is bullish on the midcap pharma names.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347